

DNA Damage in Carotid Artery Stenosis



Xin Chen, Chao Zhang, Fei Li and Tao Luo*

Department of General Surgery, Xuan Wu hospital Capital Medical University, China

Submission: September 01, 2019; **Published:** September 19, 2019

***Corresponding author:** Tao Luo, Department of General Surgery, Xuan Wu hospital Capital Medical University, No.45 Changchun Street, Beijing, China

Abstract

Carotid Artery Stenosis (CAS) is a common vascular disease affecting the elderly health in the world. Surgery is the most effective treatment for CAS, but the high restenosis rate limits the long-term success. The molecular mechanisms of CAS and restenosis is still unclear. Multiple studies have shown that DNA damage and repair present in atherosclerosis and CAS, but their relevance to the development of CAS remain unknown. In this review, we summarized the research status of DNA damage in the development and treatment of CAS..

Keywords: Carotid artery stenosis; Restenosis; DNA damage; Atherosclerosis

Abbreviations: CAS: Carotid Artery Stenosis; ROS: Reactive Oxygen Species; NADP: Nicotinamide Adenine Dinucleotide Phosphate; VSMCs: Vascular Smooth Muscle Cells; ECs: Endothelial Cells; ACEI: Angiotensin Converting Enzyme Inhibitor; IR: Ionizing Radiation

Introduction

CAS is a major cause of ischemic stroke and cardiovascular disease. At present, the most effective treatment for CAS is carotid endarterectomy or carotid artery stenting, but the high restenosis rates limit the long-term success [1,2]. Atherosclerosis is the pathology basis of CAS; intimal hyperplasia is thought to be the main cause for restenosis [3-5]. The pathogenesis of CAS has been widely studied in past decades. However, the molecular mechanisms of CAS and restenosis have not been clearly understood.

DNA damage is the destruction of DNA structure that could be generated from DNA replication or a consequence of internal and external stimulus, at a frequency of 10⁴ times per single cell per day [6]. In recent years, a number of studies demonstrated that DNA damage and repair is present in atherosclerosis and CAS [7,8]. DNA damage response involve in a variety of cellular processes including cell cycle control, cell senescence and apoptosis, which may directly or indirectly affect the atherosclerotic formation and intimal hyperplasia [9]. In this review, we summarized the current knowledge about DNA damage in the development and treatment of CAS.

Stimuli that cause DNA damage in carotid artery

Stimuli in vascular that cause DNA damage can be divided into two classes based on its origin: endogenous and exogenous. The major endogenous stimulus is Reactive Oxygen Species (ROS), that can be generated from normal cellular metabolism [10-12],

and exogenous stimuli include physical and chemical agents from outside or intracavitary.

ROS can be produced by multiple enzymes in cells, such as Nicotinamide Adenine Dinucleotide Phosphate (NADP) oxidase, lipoxygenases, xanthine oxidase and mitochondrial enzymes [13]. NADPH oxidases is thought to be the most important ROS generation system in vascular, the laminar shear stress generated by blood flow, inflammation, growth factor and cytokine in blood act as catalyzer for NADPH oxidases and promotes ROS generate [14]. ROS at normal levels is an important cellular messenger and participates in immune response. However, excessive ROS in vascular under pathological conditions can add double bonds or remove hydrogen atoms from the DNA bases, resulting in many types of DNA damage, such as mitochondrial DNA damage, bases damage, single-strand break and double-strand break [15]. The extensive expression of 8-hydroxy-2-deoxyguanosine (8-OHdG) and 7,8-dihydro-8-oxo-2-deoxyguanosine (8-oxo-dG), two oxidative DNA damage markers [16], is a common feature for advanced atherosclerosis lesions. Moreover, ROS in vascular acts directly on Vascular Smooth Muscle Cells (VSMCs) and promotes proliferation and migration, which are the key mechanism of intimal hyperplasia [17].

There is growing evidence suggesting that DNA damage-inducing treatment is related to artery stenosis. Clinical studies have shown that the increased incidence of ischemia stroke in

testicular cancer, breast cancer and Hodgkin's lymphoma patients is associated with radiation therapy and chemotherapy [18-20]. Stewart F et al. [21] demonstrated that ionizing radiation accelerates the development of atherosclerotic lesions in ApoE^{-/-} mice by promoting the aggregation of inflammatory cells in atherosclerotic plaques [21]. In patients with malignant tumor, radiation and chemotherapy may directly or indirectly induce DNA damage in carotid artery. Energy carried by ionizing radiation may deposit on DNA bases and directly induce SSBs and DSBs [22]. Also, radiation cause water ionization and produce hydroxyl to induce DNA damage indirectly [23]. Cytotoxic agents cause DNA damage through different pathways. For example, alkylation agents directly destroy DNA structure by interacting with DNA chain through active groups, and antimetabolites inhibit DNA synthesis by interfering with nucleotide metabolism.

DNA damage in the development of CAS

DNA damage and repair associated proteins appears in the early stage of atherosclerosis, and the markers of DNA damage persist in cells of atherosclerotic plaques and increase in advanced lesions [12,24], which could be the consequence of persisting stimuli or DNA damage repair deficiency is still unclear. A previous study showed the deficiency of homologous recombination, a major and highly conserved DSB repair pathway, in carotid artery tissues from patients with carotid restenosis [7]. Another study by Martin B, et al found that defective base excision repair for 8-oxoguanine oxidative lesion in atherosclerotic plaque Vascular Smooth Muscle Cells (VSMCs), due to the reduced acetylation of OGG1, accelerates the development of atherosclerosis [25]. These findings raise an important question of whether we can prevent the atherosclerosis by improvement the DNA repair efficiency. A recent study compared the formation of atherosclerotic plaques in two groups of ApoE^{-/-} mice that overexpress wild type and C-terminal deleted NBS1 in the VSMCs respectively, NBS1 would accelerate DSB repair and C-terminal deleted NBS1 delay repair, the overexpression of NBS1 in VSMCs enhanced DSB repair and improved the stability of plaques compare to another group but did not slowed the atherogenesis [26]. Therefore, the efficiency of DNA damage repair may have minimal effects on atherogenesis but may underlie some of the therapeutic benefits in preventing plaques rupture, especially in CAS.

Although there is no solid evidence that DNA damage directly influence atherogenesis and intimal hyperplasia, it has been shown that the consequences of DNA damage associate with CAS. DNA damage induces the cell cycle arrest by activating DNA damage checkpoints, which will guarantee proper time for DNA repair [27,28]. Inefficient DNA repair will sustain low level of checkpoint activation and result in cell senescence and apoptosis [29]. Mover, the CHK1- and CHK2- dependent activation of p53 can induce cell apoptosis [9,30]. The senescence and apoptosis of Endothelial Cells (ECs), VSMCs and macrophages accelerate atherosclerosis, promote features of plaque vulnerability and cause inflammation [9,26,31,32]. The cytokine, interleukin, endothelin and nitric

oxide released by senescent/ apoptotic cells and inflammation can induce VSMCs phenotype switch from contractile to secretory and phagocytic type, which will further promote the development of atherosclerosis and intimal hyperplasia [17,33-35].

DNA damage for CAS treatment

Reducing risk factors of atherosclerosis by pharmacotherapy is an effective and safe method for the prevention of CAS. For example, Angiotensin Converting Enzyme Inhibitor (ACEI) can suppress the inflammatory response and reduce ROS generation in arteries by inhibiting the generation of angiotensin and activate the angiotensin 2 [36]. Atorvastatin can reduce aldosterone-induced ROS generation and vascular inflammation through its inhibitory effects on Rac1/2 activation [37].

Irradiation as a treatment for suppressing intimal hyperplasia was widely studied in past decades, high dose of Ionizing Radiation (IR) can kill cells directly through inducing irreparable DNA damage [23,38]. IR or radioactive stent implantation at early stage can relieve intimal proliferation effectively [39]. The IR doses to treat intimal hyperplasia are generally in the range of 10 to 25 Gy to guarantee good therapeutic effect and low rates of complication [22].

A recent study showed that pharmacological inhibition of CHK1 significantly reduces vascular remodeling and improves hemodynamic parameters in pulmonary arterial hypertension rat model through suppressing DNA damage repair [40]. Furthermore, the inhibition of PARP-1, a DNA repair enzyme, attenuates neointima formation through inhibition of leukocyte infiltration in rat carotid artery after balloon injury [41]. These results suggest that inhibition of DNA damage repair enzyme may be potentially a strategy to prevent intimal hyperplasia.

Conclusion

ROS generated in vascular under pathological conditions is the main cause of DNA damage. Cell senescence, apoptosis and inflammation caused by DNA damage promotes atherogenesis and VSMCs proliferation, which is the major reason for CAS. Reducing the ROS generation in vascular by pharmacotherapy is an effective way for CAS prevention, the inhibition of DNA damage repair enzyme could benefit the prevention of intimal hyperplasia.

Acknowledgment

This work was funded by the National Natural Science Foundation of PR China Grant (81470587 to T.L.).

References

1. Clavel P (2019) Cumulative incidence of restenosis in the endovascular treatment of extracranial carotid artery stenosis: a meta-analysis. *J Neurointerv Surg* 11(9).
2. Wangqin R, Krafft PR, Piper K, Kumar J, Xu K, et al. (2019) Management of De Novo Carotid Stenosis and Postintervention Restenosis-Carotid Endarterectomy Versus Carotid Artery Stenting-a Review of Literature. *Transl Stroke Res* 10(5): 460-474.

3. Luo T, Cui S, Bian C, Yu X (2014) Crosstalk between TGF-beta/Smad3 and BMP/BMP2 signaling pathways via miR-17-92 cluster in carotid artery restenosis. *Mol Cell Biochem* 389(1-2): 169-176.
4. Dai Z, Xu G (2017) Restenosis after carotid artery stenting. *Vascular* 25(6): 576-586.
5. Marx SO, Totary-Jain H, Marks AR (2011) Vascular smooth muscle cell proliferation in restenosis. *Circ Cardiovasc Interv* 4(1): 104-111.
6. Lindahl T, Nyberg B (1972) Rate of depurination of native deoxyribonucleic acid. *Biochemistry* 11(19): 3610-3618.
7. Luo T, Cui S, Bian C, Yu X (2013) DNA double-strand break repair is activated in carotid artery restenosis. *Cell Mol Biol (Noisy-le-grand) Suppl* 59: OL1869-OL1875.
8. Moulakakis KG (2017) Oxidative injury associated with stenting of asymptomatic carotid artery stenosis. *Vasa* 46(4): 239-240.
9. Uryga A, Gray K, Bennett M (2016) DNA Damage and Repair in Vascular Disease. *Annu Rev Physiol* 78: 45-66.
10. Zhang C, Luo T, Cui S, Gu Y, Bian C, et al. (2015) Poly (ADP-ribose) protects vascular smooth muscle cells from oxidative DNA damage. *BMB Rep* 48(6): 354-359.
11. Martinet W, Knaapen MW, De Meyer GR, Herman AG, Kockx MM (2001) Oxidative DNA damage and repair in experimental atherosclerosis are reversed by dietary lipid lowering. *Circ Res* 88(7): 733-739.
12. Jacinto TA, Meireles GS, Dias AT, Aires R, Porto ML, et al. (2018) Increased ROS production and DNA damage in monocytes are biomarkers of aging and atherosclerosis. *Biol Res* 51(1): pp. 33.
13. Förstermann U, Xia N, Li H (2017) Roles of Vascular Oxidative Stress and Nitric Oxide in the Pathogenesis of Atherosclerosis. *Circ Res* 120(4): 713-735.
14. Kattoor AJ, Pothineni NVK, Palagiri D, Mehta JL (2017) Oxidative Stress in Atherosclerosis. *Curr Atheroscler Rep* 19(11): 42.
15. Uryga A, Gray K, Bennett M (2016) Bennett, DNA Damage and Repair in Vascular Disease. *Annu Rev Physiol* 78: 45-66.
16. Sliwinska A, Kwiatkowski D, Czarny P, Toma M, Wigner P, et al. (2016) The levels of 7,8-dihydrodeoxyguanosine (8-oxoG) and 8-oxoguanine DNA glycosylase 1 (OGG1) - A potential diagnostic biomarkers of Alzheimer's disease. *J Neurol Sci* 368: 155-159.
17. Bennett MR, Sinha S, Owens GK (2016) Owens, Vascular Smooth Muscle Cells in Atherosclerosis. *Circ Res* 118(4): 692-702.
18. van Leeuwen FE, Ng AK (2016) Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment. *Hematology Am Soc Hematol Educ Program* 2016(1): 323-330.
19. Haugnes HS, Bosl GJ, Boer H, Gietema JA, Brydøy M, et al. (2012) Long-Term and Late Effects of Germ Cell Testicular Cancer Treatment and Implications for Follow-Up. *J Clin Oncol* 30(30): 3752-3763.
20. Hooning MJ, Botma A, Aleman BM, Baaijens MH, Bartelink H, et al. (2007) Long-Term Risk of Cardiovascular Disease in 10-Year Survivors of Breast Cancer. *J Natl Cancer Inst* 99(5): 365-375.
21. Stewart FA, Heeneman S, Te Poele J, Kruse J, Russell NS, et al. (2006) Ionizing radiation accelerates the development of atherosclerotic lesions in ApoE^{-/-} mice and predisposes to an inflammatory plaque phenotype prone to hemorrhage. *Am J Pathol* 168(2): 649-658.
22. Fortunato JE, Glagov S, Bassiouny HS (1998) Irradiation for the treatment of intimal hyperplasia. *Ann Vasc Surg* 12(5): 495-503.
23. Ducasse E, Chevalier J, Cosset JM, Creusy C, Eschwege F, et al. (2006) Ionizing radiation to prevent arterial intimal hyperplasia at the edges of the stent: induces necrosis and fibrosis. *J Surg Res* 135(2): 331-336.
24. Martinet W, Knaapen MW, De Meyer GR, Herman AG, Kockx MM (2002) Elevated levels of oxidative DNA damage and DNA repair enzymes in human atherosclerotic plaques. *Circulation* 106(8): 927-932.
25. Shah A, Gray K, Figg N, Finigan A, Starks L, et al. (2018) Defective Base Excision Repair of Oxidative DNA Damage in Vascular Smooth Muscle Cells Promotes Atherosclerosis. *Circulation* 138(14): 1446-1462.
26. Gray K, Kumar S, Figg N, Harrison J, Baker L, et al. (2014) Effects of DNA Damage in Smooth Muscle Cells in Atherosclerosis. *Circ Res* 116(5): 816-826.
27. Barnum KJ, O'Connell MJ (2014) Cell cycle regulation by checkpoints. *Methods Mol Biol* 1170: 29-40.
28. Bartek J, Lukas J (2003) Chk1 and Chk2 kinases in checkpoint control and cancer. *Cancer Cell* 3(5): 421-429.
29. Lukas J, Lukas C, Bartek J (2004) Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time. *DNA Repair (Amst)* 3(8-9): 997-1007.
30. Jackson SP, Bartek J (2009) The DNA-damage response in human biology and disease. *Nature* 461(7267): 1071-1078.
31. Clarke MCH, Littlewood TD, Figg N, Maguire JJ, Davenport AP, et al. (2008) Chronic Apoptosis of Vascular Smooth Muscle Cells Accelerates Atherosclerosis and Promotes Calcification and Medial Degeneration. *Circ Res* 102(12): 1529-1538.
32. Matthews C, Gorenne I, Scott S, Figg N, Kirkpatrick P, et al. (2006) Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stress. *Circ Res* 99(2): 156-164.
33. Davalos AR, Coppe JP, Campisi J, Desprez PY (2010) Senescent cells as a source of inflammatory factors for tumor progression. *Cancer Metastasis Rev* 29(2): 273-283.
34. Feil S, Hofmann F, Feil R (2004) SM22alpha modulates vascular smooth muscle cell phenotype during atherogenesis. *Circ Res* 94(7): 863-865.
35. Zhang YN, Xie BD, Sun L, Chen W, Jiang SL, et al. (2016) Phenotypic switching of vascular smooth muscle cells in the 'normal region' of aorta from atherosclerosis patients is regulated by miR-145. *J Cell Mol Med* 20(6): 1049-1061.
36. Fang Y, Gao F, Liu Z (2019) Angiotensin-converting enzyme 2 attenuates inflammatory response and oxidative stress in hyperoxic lung injury by regulating NF-kB and Nrf2 pathways. *QJM pii: hcz206*.
37. Bruder-Nascimento T, Callera GE, Montezano AC, Belin de Chantemele EJ, Tostes RC, et al. (2019) Atorvastatin inhibits pro-inflammatory actions of aldosterone in vascular smooth muscle cells by reducing oxidative stress. *Life Sci* 221: 29-34.
38. Ducasse E, Creusy C, Mazurier J, Cosset JM, Eschwege F, et al. (2004) Morphometric and histological changes in the vascular wall after external radiation for the prevention of intimal hyperplasia. *J Surg Res* 117(2): 316-322.
39. Kutryk MJ, Kuliszewski MA, Jaffe R, Tio FO, Janicki C, et al. (2007) Low-energy gamma-emitting stents inhibit intimal hyperplasia with minimal "edge effects" in a pig coronary artery model. *Cardiovasc Revasc Med* 8(1): 28-37.
40. Bourgeois A, Bonnet S, Breuils-Bonnet S, Habbout K, Paradis R, et al. (2019) Inhibition of CHK1 (Checkpoint Kinase 1) Elicits Therapeutic Effects in Pulmonary Arterial Hypertension. *Arteriosclerosis, Thrombosis, and Vascular Biology* 39(8): 1667-1681.
41. Zhang C, Yang J, Jennings LK (2004) Attenuation of neointima formation through the inhibition of DNA repair enzyme PARP-1 in balloon-injured rat carotid artery. *Am J Physiol Heart Circ Physiol* 287(2): H659-H666.



This work is licensed under Creative Commons Attribution 4.0 License
DOI: [10.19080/JOCCT.2019.15.555902](https://doi.org/10.19080/JOCCT.2019.15.555902)

Your next submission with Juniper Publishers will reach you the below assets

- Quality Editorial service
- Swift Peer Review
- Reprints availability
- E-prints Service
- Manuscript Podcast for convenient understanding
- Global attainment for your research
- Manuscript accessibility in different formats
(Pdf, E-pub, Full Text, Audio)
- Unceasing customer service

Track the below URL for one-step submission

<https://juniperpublishers.com/online-submission.php>